Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health Inc. (OTCQB: ODYY) is a medical company focused on life-saving and life-enhancing medical solutions, and its news flow reflects this emphasis on critical care and diagnostic technologies. Company announcements highlight development milestones, licensing transactions, financing arrangements and strategic asset sales that shape its evolving portfolio.
Recent news has detailed Odyssey’s entry into the breast cancer diagnostics marketplace through a Master Technology and Sub-license Agreement for exclusive, worldwide rights to BreastCheck ae, a non-invasive test for breast abnormalities. Press releases describe BreastCheck ae as a home-use, temperature-based screening tool that provides results in about 15 minutes and is intended to complement established diagnostic procedures. Updates also cover regulatory status, including FDA registration in the United States and registrations with authorities in the European Union and the United Kingdom.
Odyssey’s news archive also covers progress on its Save A Life choking rescue device, a patented vacuum-based system designed to dislodge airway obstructions rapidly. The company has reported creating a prototype and planning further development with the goal of an FDA submission, illustrating how it communicates development stages and regulatory intentions to investors and stakeholders.
Another key theme in Odyssey’s news is corporate and financial strategy. Releases describe the sale of its neurological drug technology pipeline, including the concussion candidate ONP-002, to Oragenics, Inc., as well as the resulting investment in Oragenics preferred stock. Additional coverage explains long-term service contracts and financing facilities, such as the multi-year maintenance service agreement and related funding capacity with Mast Hill Fund, L.P., which the company characterizes as supporting its transition toward recurring revenue and commercialization initiatives.
Investors and observers can use the ODYY news page on Stock Titan to follow these developments, including device development updates, licensing agreements, regulatory steps, financing transactions and portfolio changes that may influence Odyssey Health’s business trajectory.
Odyssey Health, Inc. (OTC Pink: ODYY) will be featured in a C-Level interview on The RedChip Money Report®, airing June 11 at 7 p.m. ET on Bloomberg TV, reaching 73 million homes in the U.S. CEO Michael Redmond discusses Odyssey's innovative concussion treatment and other medical solutions, targeting a $400 billion market. The company focuses on unmet medical needs with products like CardioMap® and Save-A-Life®, aiming to set industry standards. The interview promises insights on human trials and strategic objectives.
Odyssey Health, Inc. (OTC Pink: ODYY) announced positive safety results from Cohort I of their Phase I clinical trial for PRV-002, a novel drug aimed at treating concussions. Conducted at Nucleus Network, the trial involved eight healthy subjects who reported no severe adverse effects, indicating that PRV-002 was well-tolerated. Vital signs and lab results remained normal. With a global concussion treatment market valued at $6.9 billion in 2020, Odyssey is optimistic about the drug's potential efficacy in future trials, as stated by executives.
Odyssey Health, Inc. (OTC Pink: ODYY) announced positive outcomes from the initial group of patients in their Phase I clinical trial for PRV-002, a novel treatment for concussions. The drug has been shown to be safe and well-tolerated in five healthy subjects, with no serious adverse events reported. Every year, over three million concussions occur in the U.S., presenting a significant unmet medical need. The company aims to complete the trial and present findings to the FDA, with plans for a subsequent Phase II trial focused on military applications.
Odyssey Health, Inc. (OTC Pink: ODYY) has appointed Vice Admiral (r) Timothy Szymanski to its Military Advisory Board. Szymanski, a veteran with over 36 years of service, aims to enhance the company's efforts in developing PRV-002, a drug designed to treat concussions. Currently in Phase 1 clinical trials, PRV-002 shows promise in neuroprotection, potentially addressing the urgent needs of millions affected by concussions annually. Odyssey focuses on life-saving medical solutions, emphasizing strategies that improve service members' well-being.
Odyssey Group International (OTC Pink: ODYY) has established a Military Advisory Board to enhance its focus on treating traumatic brain injuries (TBI) with its drug candidate, PRV-002, currently in Phase 1 clinical trials. The board includes notable military leaders such as Major General Jim Linder and Commanding General Francis Beaudette, who bring extensive experience in addressing TBIs, especially in the military context. Odyssey aims to develop an intranasal device to deliver PRV-002 for immediate treatment post-concussion, addressing a significant medical need.
Odyssey Health, Inc. (OTC Pink: ODYY) is advancing its clinical trial of PRV-002, a novel neurosteroid aimed at treating concussions. Conducted by Nucleus Network in Melbourne, the trial is significant as it seeks to address a critical gap in concussion treatment. NFL Hall of Famer Brett Favre is involved as a sports advisory board member, although he is not a participant in the trial. The medication, delivered nasally, aims to reduce brain swelling and improve recovery outcomes, with a target population that includes sports players and others at risk of brain injuries.
Odyssey Group International, Inc. (OTC Pink: ODYY) announced a $500,000 donation from Erase PTSD Now and the Glenn Greenberg and Linda Vester Foundation to support Phase 1 human clinical trials of PRV-002, a drug aimed at treating concussion. CEO Michael Redmond emphasized the significance of this funding in progressing the trials. The partnership aims to collect data on PTSD and concussion links to enhance treatment for military veterans. PRV-002 is designed to alleviate concussion symptoms and reduce brain inflammation, with the goal of improving recovery outcomes for soldiers.
Odyssey Group International, Inc. (OTC: ODYY) has filed a provisional patent for a novel nasal drug delivery device intended for treating concussions. This device uses a dual wall dispensing system to enhance drug deposition directly into the nasal cavity and olfactory region, aiming to improve treatment outcomes for traumatic brain injuries. CEO Michael Redmond emphasized the device’s potential to deliver PRV-002, a neuroprotective synthetic neurosteroid, rapidly to the brain while minimizing side effects. The company targets further development of neurological drugs utilizing this technology.
Odyssey Group International (OTC: ODYY) announced the successful initiation of its Phase 1 clinical trial for PRV-002, a nasal neurosteroid aimed at treating concussion. Enrollment and screening of subjects have commenced, with the first cohort scheduled for dosing shortly. The trial will evaluate pharmacokinetics and tolerability across three dosage levels. The unique delivery method and the pressing need for concussion treatments are expected to facilitate participant enrollment and compliance. This update indicates significant progress in Odyssey's drug development pipeline.
Odyssey Group International, Inc. (OTC: ODYY) announced its participation in the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company will present at 7:00 am EDT on September 13. Interested investors can register for the virtual conference HERE. Odyssey focuses on medical solutions, particularly its neurosteroid PRV-002 for treating concussions.